K. Bendjama, E. Quéméneur Human Vaccines and Immunotherapeutics, August 2017 – Read the article Publication
Category: 2017
First Patient Dosed in a Phase 1/2 Trial of Pexa-Vec + Opdivo® for the First-Line Treatment of Advanced Liver Cancer
PR Pexa-Vec nivo EN
Immune Checkpoint Blockade, Immunogenic Chemotherapy or IFN-α Blockade Boost the Local and Abscopal Effects of Oncolytic Virotherapy
Laetitia Fend, et al. Cancer Research, July 2017, DOI: 10.1158/0008-5472.CAN-16-2165 – Download the article Publication
Transgene Announces Cancer Research Publication Confirming the Potential of its Next Generation Armed Engineered Oncolytic Virus
20170724 PR CancerResearch
Servier and Transgene have become partners to apply viral vectorization technology to the engineering of allogenic CAR-T.
20170629 Servier Transgene EN
Transgene Hosts Immuno-Oncology R&D Day Focused on Modulating the Tumor Micro-Environment in Paris
20170622 CP RD Day EN
Combined General Meeting of June 8, 2017
20170608 TG AGM June 2017 EN
TG6002: A novel oncolytic and vectorized gene pro-drug therapy approach to treat glioblastoma
Ahmed Idbaih, et al. ASCO 2017, June 2017 – Download the abstract Abstract
€50.7 Million in Cash and Cash Equivalents as of March 31, 2017
20170425 PR Q1-2017
Transgene and Bristol-Myers Squibb Announce Clinical Research Collaboration to Evaluate TG4010 in Combination with Opdivo and Standard Chemotherapy in First Line Non-Small Cell Lung Cancer
20170425 BMS-Clinical Collaboration Release Transgene-FINAL
